• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Abexinostat

Product ID A046189
Cas No. 783355-60-2
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $115.30 In stock
25 mg $441.50 In stock
100 mg $1,412.60 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Abexinostat is an inhibitor of histone deacetylase (HDAC). While it primarily targets HDAC1, it also shows activity against HDAC2, 3, 6, 8, and 10. Abexinostat has shown synergistic effect with bortezomib in lymphoma cells, inducing caspase-dependent apoptosis in vitro. It has exhibited efficacy when used in combination with doxorubicin against metastatic sarcoma.

Product Info

Cas No.

783355-60-2

Purity

≥98%

Formula

C21H23N3O5

Formula Wt.

397.16

IUPAC Name

3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide

Synonym

PCI-24781, CRA-024781, DRA-24781

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

A046189 MSDS PDF

Info Sheet

A046189 Info Sheet PDF

References

Bhalla S., Balasubramanian S., et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 15(10):3354-65 (2009). PMID: 19417023.

Choy E., Flamand Y., et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 121(8):1223-30 (2015). PMID: 25536954.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only